CN1682722A - 马来酸氯苯那敏的新用途 - Google Patents
马来酸氯苯那敏的新用途 Download PDFInfo
- Publication number
- CN1682722A CN1682722A CN 200510037890 CN200510037890A CN1682722A CN 1682722 A CN1682722 A CN 1682722A CN 200510037890 CN200510037890 CN 200510037890 CN 200510037890 A CN200510037890 A CN 200510037890A CN 1682722 A CN1682722 A CN 1682722A
- Authority
- CN
- China
- Prior art keywords
- maleate
- chlorphenamine
- treatment
- chlophnamine
- hepatitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 title abstract 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 title abstract 4
- 239000003814 drug Substances 0.000 claims abstract description 11
- 208000006454 hepatitis Diseases 0.000 claims abstract description 11
- 231100000283 hepatitis Toxicity 0.000 claims abstract description 11
- 108010003415 Aspartate Aminotransferases Proteins 0.000 claims abstract description 8
- 102000004625 Aspartate Aminotransferases Human genes 0.000 claims abstract description 8
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 claims description 20
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 claims description 3
- 108010082126 Alanine transaminase Proteins 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000007924 injection Substances 0.000 abstract description 3
- 238000002347 injection Methods 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- AELCINSCMGFISI-DTWKUNHWSA-N (1R,2S)-tranylcypromine Chemical compound N[C@@H]1C[C@H]1C1=CC=CC=C1 AELCINSCMGFISI-DTWKUNHWSA-N 0.000 abstract 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract 1
- 235000004279 alanine Nutrition 0.000 abstract 1
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 11
- 229960003291 chlorphenamine Drugs 0.000 description 7
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 108090000340 Transaminases Proteins 0.000 description 4
- 102000003929 Transaminases Human genes 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 229960001340 histamine Drugs 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000003834 Histamine H1 Receptors Human genes 0.000 description 1
- 108090000110 Histamine H1 Receptors Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 230000003153 cholinolytic effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明公开了一种马来酸氯苯那敏的新用途，其特征在于用于治疗肝炎，用于降低丙氨酸转氨酶ALT、天门冬氨酸氨基转移酶AST。治疗肝炎时，马来酸氯苯那敏可以单独给药，也可以作为组合药物中的一种组分给药，其剂型可以是口服剂、针剂等，给药方式可以是口服、或注射。其治疗剂量需要根据患者的年龄、体能、疾病严重程度及给药途径来确定。
Description
技术领域
本发明属于一种药物马来酸氯苯那敏的新用途，具体而言是马来酸氯苯那敏在治疗肝炎药物中的用途。
背景技术
马来酸氯苯那敏又名扑尔敏，为组胺拮抗剂，通过与组胺竞争组胺H1受体而对抗组胺的过敏作用；但不影响组胺的代谢，也不阻止组胺的释放；扑尔敏还有抗胆碱M受体作用，作用于胆碱毒蕈样受体，使得鼻黏膜干燥。临床主要用于治疗过敏性鼻炎、皮肤黏膜的过敏。
发明内容
本发明的内容是发现了马来酸氯苯那敏在治疗肝炎方面的用途。
马来酸氯苯那敏的新用途，是用于治疗肝炎。
马来酸氯苯那敏的新用途在于用于降低丙氨酸转氨酶ALT、天门冬氨酸氨基转移酶AST。
本发明提供一种治疗肝炎的药物，在于其中含用治疗有效量的马来酸氯苯那敏及药用载体或赋形剂。
马来酸氯苯那敏临床用于治疗肝炎，具有保肝降酶作用，主要作用在于降低转氨酶ALT(丙氨酸转氨酶)、AST(天门冬氨酸氨基转移酶)等。可以与其他治疗肝炎的药物、保肝的药物及维生素类药物等配合制成新的剂型，方便应用。
治疗肝炎时，马来酸氯苯那敏可以单独给药，也可以作为组合药物中的一种组分给药，其剂型可以是口服剂、针剂等，给药方式可以是口服、或注射。其治疗剂量需要根据患者的年龄、体能、疾病严重程度及给药途径来确定。
具体实施方式
以下的实施例是对本发明的进一步祥细说明并不意味着对本发明有任何限制。
对CCl4所致急性肝损伤小鼠，下表为实验结果。
扑尔敏对CCl4所致急性肝损伤小鼠血清转氨酶的影响
| 组别 | 剂量(mg/kg) | 动物数(只) | 血清转氨酶活力单位(u/100ml)ALT AST |
| 正常对照模型对照扑尔敏 | -10ml/kg 0.1％CCl43+CCl49+CCl427+CCl4 | 1010101010 | 85.21±26.45 101.1±74.2182.87±67.50 179.7±42.3146.60±57.21 187.5±41.2109.37±40.09 155.8±23.451.35±20.52 144.1±16.7 |
试验数据表明：扑尔敏用药组9mg/kg可明显降低ALT活力；扑尔敏用药组27mg/kg对AST有明显抑制作。两者相比对ALT降低作用更强。
结论：扑尔敏对肝损伤小鼠血清转氨酶ALT、AST升高有明显降低作用。
Claims (3)
1、马来酸氯苯那敏的新用途，其特征在于用于治疗肝炎。
2、根据权利要求1所述的马来酸氯苯那敏的新用途，其特征在于用于降低丙氨酸转氨酶ALT、天门冬氨酸氨基转移酶AST。
3、治疗肝炎的药物，其特征在于其中含用治疗有效量的马来酸氯苯那敏及药用载体或赋形剂。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100378904A CN1297272C (zh) | 2005-02-25 | 2005-02-25 | 马来酸氯苯那敏的新用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100378904A CN1297272C (zh) | 2005-02-25 | 2005-02-25 | 马来酸氯苯那敏的新用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1682722A true CN1682722A (zh) | 2005-10-19 |
| CN1297272C CN1297272C (zh) | 2007-01-31 |
Family
ID=35262342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100378904A Active CN1297272C (zh) | 2005-02-25 | 2005-02-25 | 马来酸氯苯那敏的新用途 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1297272C (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111084808A (zh) * | 2019-12-29 | 2020-05-01 | 广东罗浮山国药股份有限公司 | 咳特灵制剂在治疗乙型肝炎中的应用 |
| CN111450143A (zh) * | 2020-04-24 | 2020-07-28 | 广州白云山医药集团股份有限公司白云山制药总厂 | 小叶榕提取物在制备预防和/或治疗肝脏病变的药物中的用途 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1209113C (zh) * | 2003-08-15 | 2005-07-06 | 罗笑宇 | 一种治疗银屑病的酊剂 |
-
2005
- 2005-02-25 CN CNB2005100378904A patent/CN1297272C/zh active Active
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111084808A (zh) * | 2019-12-29 | 2020-05-01 | 广东罗浮山国药股份有限公司 | 咳特灵制剂在治疗乙型肝炎中的应用 |
| CN111450143A (zh) * | 2020-04-24 | 2020-07-28 | 广州白云山医药集团股份有限公司白云山制药总厂 | 小叶榕提取物在制备预防和/或治疗肝脏病变的药物中的用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1297272C (zh) | 2007-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10787502B2 (en) | Mast cell stabilizers for treatment of hypercytokinemia and viral infection | |
| JPS6143112A (ja) | 精神性欲機能障害治療剤 | |
| TW200412960A (en) | Potent inhibitor of HCV serine protease | |
| TW200412934A (en) | Pharmaceutical formulations of modafinil | |
| GB2430623A (en) | Medicaments for treating chronic respiratory disease | |
| KR20110014199A (ko) | 비강 비염 치료용 재조합 인간 ｃｃ10 및 이의 조성물 | |
| JP2019031551A (ja) | 女性胃不全麻痺に関係する症状の処置 | |
| WO2022232179A9 (en) | Novel n,n-dimethyltryptamine compositions and methods | |
| WO2011097148A3 (en) | Use of oral heparin preparations to treat urinary tract diseases and conditions | |
| Elbaridi et al. | Current concepts of phenylpiperidine derivatives use in the treatment of acute and chronic pain | |
| US6281222B1 (en) | Compositions and method for treatment of acetaminophen intoxication | |
| CN1297272C (zh) | 马来酸氯苯那敏的新用途 | |
| JP2006096749A (ja) | 感冒用医薬組成物 | |
| WO2017088749A1 (zh) | 一种治疗溃疡性结肠炎的药物组合物 | |
| US20150080417A1 (en) | Therapeutic composition to treat lesions caused by herpes simplex virus | |
| CN1669562A (zh) | 筋骨康复膏及其制备方法 | |
| US20040152733A1 (en) | Duloxetine for treatment of hot flashes | |
| CN107308121A (zh) | 肝脏再生的治疗剂 | |
| Singh et al. | Effect of Preoperative Intravenous and Inhalational Dexmedetomidine on the Hemodynamic Response of Laryngoscopy: A Prospective Double-blinded Randomized Study | |
| CN117797155B (zh) | 对抗氯胺酮毒性的药物制剂 | |
| US11452754B2 (en) | Pharmaceutical composition and uses thereof | |
| CN106727610A (zh) | 一种治疗病毒性心肌炎的西药组合物及其应用 | |
| MacConnachie | Zanamivir (Relenza®)—A new treatment for influenza | |
| WO2002043737A1 (en) | Treatment of chronic fatigue syndrome and fibromyalgia syndrome | |
| WO2015027847A2 (zh) | 含有奥司他韦羧酸胍基类似体和/或其乙酯制剂的给药方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: HENAN JIUSHI PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: WANG XIAOSHAN Effective date: 20080411 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20080411 Address after: Huixian City, Henan Province Zhou Bu village southeast nine potential pharmaceutical Co. Ltd. Patentee after: Henan Jiushi Pharmaceutical Co., Ltd. Address before: Mei Shan Road, Anhui University of Traditional Chinese Medicine, Anhui, Hefei College of pharmacy Patentee before: Wang Xiaoshan |
|
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: Huixian City, Henan province 453600 week package southeast nine pharmaceutical company limited potential Patentee after: Henan Jiushi Pharmaceutical Co., Ltd. Address before: Huixian City, Henan province 453600 week package southeast nine pharmaceutical company limited potential Patentee before: Henan Jiushi Pharmaceutical Co., Ltd. |
|
| PP01 | Preservation of patent right | ||
| PP01 | Preservation of patent right |
Effective date of registration: 20190308 Granted publication date: 20070131 |
|
| PD01 | Discharge of preservation of patent | ||
| PD01 | Discharge of preservation of patent |
Date of cancellation: 20220308 Granted publication date: 20070131 |
|
| PP01 | Preservation of patent right | ||
| PP01 | Preservation of patent right |
Effective date of registration: 20220308 Granted publication date: 20070131 |